Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Encephalitogenic peptide and platelet aggregation in multiple sclerosis.

M Prosiegel, I Neu, L Mehlber

    Acta Neurologica Scandinavica
    |February 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Management of dysphagia in acute stroke : A prospective study for validation of current recommendations].

    Der Nervenarzt·2017
    Same author

    [FEES for neurogenic dysphagia: training curriculum of the German Society of Neurology and the German Stroke Society].

    Der Nervenarzt·2014
    Same author

    Long-term functional outcome in patients with neurogenic dysphagia.

    NeuroRehabilitation·2014
    Same author

    [FEES in the stroke unit: recommendations for implementation in the clinical routine].

    Der Nervenarzt·2013
    Same author

    [Management of dysphagic patients with acute stroke].

    Der Nervenarzt·2012
    Same author

    Pneumonia and in-hospital mortality in the context of neurogenic oropharyngeal dysphagia (NOD) in stroke and a new NOD step-wise concept.

    Journal of neurology·2010

    Platelet aggregation (PA) was significantly higher in multiple sclerosis (MS) patients when stimulated by encephalitogenic peptide (EP). This suggests EP-stimulated platelets may contribute to MS pathogenesis by impacting brain blood vessel permeability.

    Area of Science:

    • Neuroimmunology
    • Hematology
    • Pathophysiology

    Background:

    • Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
    • The role of platelet activation in MS pathogenesis is not fully understood.
    • Encephalitogenic peptides (EPs) are implicated in MS, but their direct effect on platelet aggregation requires further investigation.

    Purpose of the Study:

    • To compare platelet aggregation (PA) in multiple sclerosis (MS) patients versus controls.
    • To investigate the effect of encephalitogenic peptide (EP) on PA in MS.
    • To determine if EP-stimulated PA differs between MS patients and those with other neurological diseases (OND).

    Main Methods:

    • Platelet aggregation was measured in 83 MS patients and 70 OND subjects.

    Related Experiment Videos

  • Two stimuli were used: encephalitogenic peptide (EP) and adenosine diphosphate (ADP).
  • Statistical analysis compared PA levels between the MS and OND groups for each stimulus.

    • Main Results:

    • EP-stimulated PA was significantly increased in MS patients compared to OND controls.
    • ADP-induced PA showed no significant difference between MS patients and OND controls.
    • These findings highlight a specific abnormality in platelet response to EP in MS.

    Conclusions:

    • Platelet aggregation stimulated by EP is elevated in MS patients.
    • EP-stimulated platelets may play a role in MS pathogenesis.
    • This effect could be mediated by altered venular permeability in the brain.